Triple Regulator (TIA-39-C20)

Triple Regulator (TIA-39-C20)

Price range: $200.00 through $600.00

Categories: , , ,
Share
Tweet
Pinterest
Email
  • Money Back Guarantee
  • Top Quality Vegan Item
  • Fast & Secure Checkout

product description

Triple Regulator (TIA-39-C20) (12mg)

Peptide Receptor Modulator Research Series – Single, Dual, and Triple Agonist Investigational Compounds.

Product Specifications
CAS Number 2381089-83-2
Molecular Formula C221H342N46O68
Molecular Weight (g/mol) 4731.33
Amino Acid Count 39
Amino Acid Sequence H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(γ-Glu-(AEEA)-C20-diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Purity ≥99% by HPLC | COA available
Physical Form Lyophilized powder
Solubility Soluble in bacteriostatic water; consult COA for specific solvent recommendations
Storage Conditions Store at -20°C; protect from light and moisture; reconstitute with bacteriostatic water

For Research Use Only. Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures.

This product is sold exclusively for in-vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic and has not been approved by the U.S. Food and Drug Administration for any use. This product is not intended to diagnose, treat, cure, mitigate, or prevent any disease. Not for human or animal consumption.

Published Literature
+
# Reference Link
[01] Jastreboff A.M., Aronne L.J., Ahmad N.N., et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 2022;387:205–216. NEJM
PubMed
[02] Garvey W.T., Frias J.P., Jastreboff A.M., et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes: SURMOUNT-2. Lancet. 2023;402(10402):613–626. PubMed
[03] Wadden T.A., Chao A.M., Machineni S., et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: SURMOUNT-3. Nature Medicine. 2023;29:2909–2918. PubMed
Journal
[04] Aronne L.J., Sattar N., Horn D.B., et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: SURMOUNT-4. JAMA. 2024;331(1):38–48. PubMed
Full Text
[05] Frias J.P., Davies M.J., Rosenstock J., et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 2021;385:503–515. PubMed
NEJM
[06] Del Prato S., Kahn S.E., Pavo I., et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk: SURPASS-4. Lancet. 2021;398(10313):1811–1824. PubMed
[07] Malhotra A., Grunstein R.R., Fietze I., et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N. Engl. J. Med. 2024;391:1193–1205. PubMed
NEJM
[08] Loomba R., Hartman M.L., Lawitz E.J., et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 2024;391:299–310. PubMed
NEJM
[09] Jastreboff A.M., le Roux C.W., Stefanski A., et al. Tirzepatide for obesity treatment and diabetes prevention. N. Engl. J. Med. 2025;392:958–971. PubMed
NEJM
[10] Aronne L.J., Sattar N., Horn D.B., et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 2025. PubMed
NEJM
Receptor Binding Profile
+
Compound Primary Receptor Target Binding / Activity Profile Reported Potency / Affinity Functional Effect
Retatrutide GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR) Triple hormone receptor agonist; binds to and activates GIPR, GLP-1R, and GCGR, with stronger reported activity at GIPR compared with GLP-1R and GCGR Human receptor EC50 values reported: GIPR: 0.0643 nM; GLP-1R: 0.775 nM; GCGR: 5.79 nM Activates multi-receptor incretin and glucagon signaling pathways associated with glucose regulation, reduced calorie intake through GIPR/GLP-1R pathways, and increased energy expenditure through GCGR activity in pharmacology studies (sciencedirect.com)

additional information

Dose

10mg, 12mg, 24mg, 60mg

product reviews

related vegan products